Lenacapavir is a long-acting HIV-1 capsid inhibitor that targets the HIV capsid protein at multiple stages of the viral life cycle. It is a highly potent antiretroviral agent developed for the treatment and prevention of HIV-1 infection in approved clinical settings.
Lenacapavir has a distinctive mechanism compared with conventional antiretroviral classes because it directly targets the HIV capsid, interfering with both early and late stages of viral replication.
Lenacapavir is a specialized antiretroviral pharmaceutical API requiring controlled multi-step chemical synthesis, purification and extensive solid-state characterization.
Important quality attributes include identity, assay, related substances, stereochemical purity, water content, residual solvents, elemental impurities, polymorphic form and stability.
CAS Number: 2188589-43-6
Molecular Formula: C39H32ClF10N7O5S2
Molecular Weight: 968.34 g/mol
Drug Class: Antiretroviral Agent
Pharmacological Class: HIV-1 Capsid Inhibitor
Therapeutic Class: Antiviral
Therapeutic Area: Infectious Diseases / HIV
Lenacapavir binds directly to the HIV-1 capsid protein and interferes with capsid function.
Its activity affects multiple stages of the viral life cycle, including:
This multi-stage mechanism distinguishes lenacapavir from reverse transcriptase, protease and integrase inhibitors.
Lenacapavir is used in approved settings for:
The specific indication, dosing schedule and formulation depend on the applicable regulatory approval.
Lenacapavir has a very long pharmacokinetic half-life, enabling extended dosing intervals. Depending on the approved regimen, it may be administered using subcutaneous injection and/or oral administration as part of an initiation or maintenance regimen.
Its long-acting characteristics make it particularly relevant to HIV treatment and prevention strategies where infrequent dosing may improve adherence.
Typical API manufacturing may involve:
Lenacapavir API quality evaluation may include:
Lenacapavir should be stored in a tightly closed container under controlled pharmaceutical storage conditions, protected from excessive heat, moisture and direct light. Final storage requirements should be established through validated stability studies.
Lenacapavir is relevant to research involving:
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 2.0 – 4.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |